Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Jade Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
JBIO
Nasdaq
2836
jadebiosciences.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Jade Biosciences, Inc.
Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Nov 13th, 2026 5:00 am
Jade Biosciences to Participate in Upcoming Conferences
- Nov 3rd, 2026 5:00 am
Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
- Oct 21st, 2026 5:00 am
Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
- Sep 30th, 2026 5:00 am
Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?
- Jun 30th, 2026 7:21 am
Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors
- Jun 26th, 2026 5:00 am
Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Jun 5th, 2026 2:01 pm
Jade Biosciences Announces Pricing of Public Offering of Common Stock
- Jun 3rd, 2026 8:58 pm
Jade Biosciences Announces Proposed Underwritten Public Offering
- Jun 3rd, 2026 2:01 pm
Jade Biosciences’ JADE101 Delivers Deep IgA Cuts, Clearing Path for Kidney Trials
- Jun 1st, 2026 7:07 pm
Jade Biosciences Announces Positive Interim Phase 1 Results for JADE101 Demonstrating Potential Best-in-Class Profile and Every-12-Week Dosing in IgA Nephropathy
- Jun 1st, 2026 5:00 am
Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy
- May 29th, 2026 2:05 pm
Assessing Jade Biosciences (JBIO) Valuation After Recent Share Price Weakness And Longer Term Gains
- May 28th, 2026 7:03 pm
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
- May 7th, 2026 2:05 pm
Jade Biosciences Appoints Edward R. Conner, M.D., as Chief Medical Officer
- Apr 22nd, 2026 5:00 am
Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth
- Mar 28th, 2026 6:14 am
Scroll